Metabolic characteristics of GS-NS0 Myeloma cells producing anti-cd25 monoclonal antibody in serum-free culture

Transcription

1 生物工程学报 Chin J Biotech 2009, July 25; 25(7): journals.im.ac.cn Chinese Journal of Biotechnology ISSN cjb@im.ac.cn 2009 Institute of Microbiology, CAS & CSM, All rights reserved 组织工程与细胞培养 -CD25 GS-NS0 赵亮, 范里, 张旭, 谭文松, : 抗 -CD25 单克隆抗体作为免疫抑制剂拥有广阔的市场前景和巨大的经济价值 本实验以表达抗 CD25 单克隆抗体的 GS-NS0 细胞为研究对象, 开发了支持其大规模培养和抗体表达的无血清低蛋白培养基, 批培养最大活细胞密度和最大抗体浓度分别达 cells/ml 和 300 mg/l 以上, 比商业无血清培养基 (Excell % primatone) 分别提高了 100% 和 46% 通过批培养实验, 研究了细胞的生长 葡萄糖和氨基酸代谢 以及产物表达特点, 并揭示了批培养过程中初始葡萄糖浓度对 GS-NS0 细胞生长与代谢的影响规律 为优化 GS-NS0 细胞培养过程和抗 CD25 单抗成功迈向产业化提供了重要的科学依据 : GS-NS0 细胞, 无血清培养基, 抗 CD25 单克隆抗体, 代谢特性 Metabolic characteristics of GS-NS0 Myeloma cells producing anti-cd25 monoclonal antibody in serum-free culture Liang Zhao, Li Fan, Xu Zhang, and Wensong Tan State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai , China Abstract: As an immunodepressant, anti-cd25 monoclonal antibody has a huge market with wide prospect and economic value. We developed a low protein serum-free medium for large-scale GS-NS0 myeloma cell culture and anti-cd25 monoclonal antibody production. Further study focused on the characteristics of GS-NS0 cell growth, glucose and amino acid metabolism, and antibody production. In the serum-free medium, the maximal viable cell density and antibody concentration reached above cells/ml and 300 mg/l in batch culture. Compared with the commercial serum-free medium (Excell % Primatone), the maximal viable cell density doubled and the maximal antibody concentration increased 46%. Results also showed the specific growth rate decreased when the glucose concentration was lower than 6 mmol/l. And the production of lactate increased when glucose concentration was excessively high (>30 mmol/l). These results were important to provide technique and theory basis for developing optimized GS-NS0 cell culture and anti-cd25 monoclonal antibody production processes. Keywords: GS-NS0 cell, serum-free medium, anti-cd25 monoclonal antibody, metabolic characteristics Anti-CD25(IL-2Rα) T 1992 Hiesse Anti-CD25 ( LO-TACT-1) Received: March 12, 2009; Accepted: May 11, 2009 Supported by: National Natural Science Foundation of China (No ). Corresponding author: Wensong Tan. Tel: ; Fax: ; wstan@ecust.edu.cn 国家自然科学基金项目 (No ) 资助

2 1070 ISSN CN /Q Chin J Biotech July 25, 2009 Vol.25 No.7 [1] LO-Tact-1, [2,3],, LO-Tact-1 2,,,, GS-NS0 NS0 [4] [5,6] [7,8],,, Anti-CD25 GS-NS0, Technopharm Anti-CD25 ( LO-TACT-1) GS-NS0, GS-NS0, GS-NS0 CD25, GS, 1 材料与方法 1.1 细胞株 GS-NS0, CD25 LO-Tact-1 [9], 1.2 培养基 DMEM/F12(1:1), HEPES Pluronic F68,, Millipore 0.1 μm Sigma-Aldrich 1.3 细胞培养系统和培养方法 GS-NS0, ~ cells/ml, 36.8 o C 5% CO 2, 50 r/min, GS-NS0, 1200 r/min 5 min,, ~ cells/ml, 60 ml, 36.8 o C 5% CO 2, 50 r/min 12 h,, 3000 r/min 10 min, GS-NS0, 1200 r/min 5 min,, ~ cells/ml (2 L BIOSTAT B, B.Braun, MFCS/win1.1), 2 L : ph (7.0 ± 0.1), DO 50%, 36.8 o C, 50 r/min 12 h,, 3000 r/min 10 min, 1.4 测定和分析方法 ml 24, 0.4%,, 3, GOD-POD ( ) :,, 4-, 505 nm (

3 : Anti-CD25 GS-NS ) : NAD +, LDH, NAD + NADH, (PMS) (NBT), 530 nm Berthelot ( ),, 5 mmol/l NH 4 Cl :,, 550 nm Waters AccQ Tag, (1525 Binary HPLC pump, 717plus Autosampler, 2487 Dual λ absorbance detector, Nova-Pak C18 4 μm 3.9 mm 150 mm column, Waters), ELISA [10] 1:200 IgG1, 100 μl/ 96, 37 o C 2 h 4 o C (16~18 h) 3,, 200 μl/, 37 o C 2 h 3, 5 min/ 100 μl/, 37 o C 1 h 3, 5 min/ 1:500 HRP- Kappa, 100 μl/, 37 o C 1 h 10, 5 min/ 100 μl/ TMB, 5 min, 50 μl/, 450 nm, 655 nm Zymed 2 结果与讨论 2.1 混合脂添加剂对 GS-NS0 细胞生长的影响 NS0 [11], [11 13], NS0, NS0, NS0-I3 ( E ) 1 CLC(Gibco) NS0-I3 GS-NS0 图 1 混合脂添加剂对 GS-NS0 细胞生长的影响 Fig. 1 Effect of complex lipids on GS-NS0 cell growth.,,, CLC NS0-I3, NS0-I3,, CLC, 0.5 d 无血清低蛋白培养基开发 DMEM/F12 (1:1), (Insulin) (Transferrin) NS0-I3, GS-NS0, LP3.6,, 10 mg/l, 2b LP3.6 GS-NS0,,,,,,, (Excell % Primatone) ( 2a) LP3.6 GS-NS0, 0.75 d cells/ml 307 mg/l, (Excell %

4 1072 ISSN CN /Q Chin J Biotech July 25, 2009 Vol.25 No.7 Primatone) 114% 103% 46%, 30%, ( 1) ;, (15~58 h),, 4 Y Lac/Gluc 1.23 mmol/mmol, 60% 图 2 GS-NS0 细胞在 Excell 620 和 LP3.6 培养基中的形态 Fig. 2 Morphology of GS-NS0 cells cultivated in Excell 620 and LP3.6 (40 ). 表 1 Excell620 和 LP3.6 培养基中细胞生长和产物表达 Table 1 Cell growth and antibody production in Excell 620 and LP3.6 media Excell 620 LP3.6 X v max (10 6 cells/ml) μ (1/d) Duration (h) IVC (10 9 cells d/l) Max antibody concentration. (mg/l) IVC was calculated until the viability decreased to approximately 50%. 图 3 Fig. 3 GS-NS0 细胞批培养的生长曲线 Growth curve of GS-NS0 cells in batch culture. 2.3 GS-NS0 细胞的生长 代谢及抗体表达 GS-NS0 2 L cells/ml LP3.6, 91.7%,, 91 h, cells/ml, cells/ml, 0.85 d 1, 0.73 d 1, 图 4 GS-NS0 细胞批培养中的葡萄糖与乳酸代谢 Fig. 4 Metabolism of glucose and lactate in batch culture of GS-NS0 cells., 69 h, 5 mmol/l,,,,

5 : Anti-CD25 GS-NS0 1073, GS, ;, α-, ( ) α- ( ), α- GS-NS0,, 5,,, 2 mmol/l,,, 1.90 mmol/l, 1.5, 3 mmol/l,,,, GS-NS0,,, (Tyr) (Cys) (His) (Met) (Phe) (Lys) (Trp) (Val) (Thr) (Arg) (Leu) (Ile),, (Ala) (Gly) (Asp) (Asn) (Pro) (Ser) 6,,,, 图 6 Fig. 6 批培养过程中的其他氨基酸浓度变化 Concentrations of amino acids in batch culture. 图 5 批培养过程中谷氨酸 谷氨酰胺 氨和丙氨酸的浓度变化 Fig. 5 Concentrations of glutamate, glutamine, ammonia, and alanine in batch culture mmol/(10 9 cells d), 0.58 mmol/(10 9 cells d) 2,, 0.15 mmol/(10 9 cells d),,, 0.23 mmol/(10 9 cells d) 2.3.4, 69 h,,,, 301 mg/l

6 1074 ISSN CN /Q Chin J Biotech July 25, 2009 Vol.25 No.7, IVC ( 7),, (R 2 = ),, 24.4 mg/(10 9 cells d) GS-NS0 CD25,, (IVC), 表 2 批培养过程中氨基酸的比消耗速率 Table 2 Specific rates of amino acids in batch culture Amino acids Sp. rate Amino acids Sp. rate Asp Arg Glut Ala Gly Pro Gln Tyr Met Lys Ile Phe Lue Trp His Cys Thr Val Unit: mmol/(10 9 cells d). (Batch-1) 24 mmol/l(batch-2) 66 mmol/l (Batch-3),,, NaCl KCl, 3 Batch-1,, cells/ml; Batch-2,, ; Batch-3,,, cells/ml,, 表 3 各批批培养的细胞生长 代谢和产物表达 Table 3 Growth, metabolism, and antibody production of GS-NS0 cells in batches Batch-1 Batch-2 Batch-3 X vmax (10 6 cells/ml) μ (1/d) IVC (10 9 cells d/l) Max antibody conc. (mg/l) q Gluc (mmol/(10 9 cells d)) q Lac (mmol/(10 9 cells d)) Y Lac/Gluc (mmol/mmol) q Antibody (mg/(10 9 cells d)) 图 7 批培养过程中的抗体累积生成量与 IVC 的关系 Fig. 7 Relationship of cumulative antibody production and IVC in batch culture GS-NS0 2 L,, GS-NS0 15 mmol/l, 8 GS-NS0, 6 mmol/l, GS-NS0, 0.66 ~ 0.81 d 1 6 mmol/l,,, ( 9),

7 : Anti-CD25 GS-NS0 1075,, Batch-3 Batch-2, IVC Batch-2,, 24 mg/(10 9 cells d), IVC, IVC Batch-2,, 301 mg/l, 3 结论 图 8 葡萄糖浓度对 GS-NS0 细胞比生长速率的影响 Fig. 8 Effect of glucose concentration on specific growth rate of GS-NS0 cells. 图 9 葡萄糖浓度对葡萄糖比消耗速率的影响 Fig. 9 Effect of glucose concentration on specific glucose consumption rate. 5.47~7.63 mmol/(10 9 cells d), GS-NS0, (Batch-3),, mmol/(10 9 cells d) Batch-1 Batch-2 24 mmol/l,, 1.30~1.46 mmol/mmol ; Batch-3, 30 mmol/l, 2, Batch-1 Batch-2 2,,, Batch mmol/l, GS-NS0, LP3.6,,, 10 mg/l, GS-NS0 GS-NS0 CHO,, GS-NS0 6 mmol/l,,, 6 mmol/l,, 24 mmol/l,, (>30 mmol/l), CD25,, 24 mg/ (10 9 cells d), IVC,, REFERENCES [1] Hiesse C, Lantz O, Kriaa F, et al. Treatment with Lo-Tact-1, a monoclonal antibody to the interleukin-2 receptor, in kidney transplantation. Presse Med, 1991, 20(40):

8 1076 ISSN CN /Q Chin J Biotech July 25, 2009 Vol.25 No.7 [2] Hiesse C, Kriaa F, Alard P, et al. Prophylactic use of the IL-2 receptor specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation. Transpl Int, 1992, 1: [3] Reding R, Feyaerts A, Vraux H, et al. Prophylactic immunosuppression with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 versus OKT3 in liver allografting. A two-year follow-up study. Transplantation, 1996, 61(9): [4] Spens E, Haggstrom L. Defined protein-free NS0 myeloma cell cultures: Stimulation of proliferation by conditioned medium factors. Biotechnol Prog, 2005, 21: [5] Zhou WC, Chen CC, Buckland B, et al. Fed-batch culture of recombinant NS0 myeloma cells with high monoclonal antibody production. Biotechnol Bioeng, 1997, 55: [6] Burky JE, Wesson MC, Young A, et al. Protein-free fed-batch culture of non-gs NS0 cell lines for production of recombinant antibodies. Biotechnol Bioeng, 2007, 96(2): [7] Lengwehasatit I, Dickson AJ. Analysis of the role of GADD153 in the control of apoptosis in NS0 myeloma cells. Biotechnol Bioeng, 2002, 80(7): [8] O Connor KC, Muhitch JW, Lacks DJ, et al. Modeling suppression of cell death by Bcl-2 over-expression in myeloma NS0 6A1 cells. Biotechnol Lett, 2006, 28(23): [9] Huang YB, Zhang Y, Sun JR, et al. An immunosuppressant: Anti-CD25 chimeric monoclonal antibody: CN 黄阳滨, 张翊, 孙九如, 等. 一种免疫抑制剂 - 抗 CD25 嵌合单克隆抗体 : CN [10] Chinese Pharmacopoeia Commission. Pharmacopoeia of The People s Republic of China Ed., Volume III. Beijing: Chemical Industry Press, 2005: Appendix 国家药典委员会. 中华人民共和国药典 年版三部. 北京 : 化学工业出版社, 2005: 附录 [11] Keen MJ, Steward TW. Adaptation of cholesterol -requiring NS0 mouse myeloma cells to high density growth in a fully defined protein-free and cholesterol-free culture medium. Cytotechnology, 1995, 17: [12] Birch JR, Boraston RC, Metcalfe H, et al. Selecting and designing cell lines for improved physiological characteristics. Cytotechnology, 1994, 15: [13] Hartman TE, Sar N, Genereux K, et al. Derivation and characterization of cholesterol-independent non-gs NS0 cell lines for production of recombinant antibodies. Biotechnol Bioeng, 2006, 96(2): 科学出版社科学出版中心生命科学分社新书推介 李宁朱作言等著 年 6 月出版